GLP-1 and insulin resistance: what TikTok gets right and wrong

What did @glpwithviv actually say?

Viv shared that she was pre-diabetic before starting GLP-1 medication, and that this health concern was a major reason she advocates for the drug class. Her clearest claim: "I don't even plan to ever stop taking a GLP1 as long as I have access, as long as I can afford it." She framed long-term, possibly indefinite use as a personal health decision she does not regret.

This is not a medical claim in the traditional sense. She is not saying GLP-1s cure diabetes or reverse pre-diabetes permanently. She is saying she intends to stay on the medication indefinitely, which is a meaningful distinction. The video is personal testimony, not a treatment protocol. But it does implicitly suggest that long-term use is both safe and rational for people in her situation, and that framing deserves scrutiny.

Does the science back this up?

Mostly, yes. The evidence for long-term GLP-1 use is actually stronger than most people realize, particularly for people with pre-diabetes or metabolic disease. The data consistently shows that stopping GLP-1 medication leads to weight regain and a return of metabolic markers toward baseline.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed participants who stopped semaglutide after 68 weeks. Within one year of stopping, two-thirds of lost weight had returned. Blood sugar, blood pressure, and lipid markers also reverted toward pre-treatment levels. This is not a side effect of a bad drug. It reflects that obesity and insulin resistance are chronic conditions, not temporary ones that get fixed and stay fixed.

For pre-diabetes specifically, the SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide reduced cardiovascular events in overweight adults with established cardiovascular disease. Separate analyses of pre-diabetic populations have shown GLP-1 use can delay or prevent progression to type 2 diabetes, though whether this benefit persists long-term without continued medication is still being studied.

Long-term safety data through 2-5 years is reasonably reassuring, though we do not yet have decades of population-level data on indefinite use.

What did they get wrong (or right)?

Viv got the core framing right. She is not overselling a cure. She is describing chronic disease management, which is exactly how most endocrinologists now think about GLP-1 therapy. The comparison to someone with hypertension staying on a beta-blocker indefinitely is not a stretch.

What she glossed over, understandably for a short TikTok, is that "as long as I can afford it" is doing a lot of heavy lifting in that sentence. Access and cost are not minor footnotes. Brand-name semaglutide can exceed $900 per month without insurance coverage, and coverage remains inconsistent, particularly for weight management rather than type 2 diabetes diagnoses. The moment someone cannot afford it, the rebound data from the STEP 1 extension becomes their reality.

She also does not mention that individual response varies. Not everyone who starts a GLP-1 for pre-diabetes sees the same glycemic benefit. Some people tolerate the medication poorly long-term. Advocating for the drug class broadly is reasonable, but framing it as a universally regret-free experience flattens a more complicated clinical picture that includes gastrointestinal side effects, rare but serious risks like pancreatitis, and the need for ongoing monitoring.

What should you actually know?

If you are pre-diabetic and considering a GLP-1, the evidence supporting that decision is legitimate. Pre-diabetes affects roughly 38% of U.S. adults (CDC, 2024), and the progression to type 2 diabetes is not inevitable but is also not self-correcting without meaningful intervention. GLP-1 medications represent one of the more effective pharmacological tools available for people in this metabolic window.

The key things to understand before committing to long-term use:

• Stopping the medication typically means losing its benefits. This is not a character flaw or a failure. It reflects the biology of chronic metabolic disease.
• Long-term safety surveillance is ongoing. Two to five year data is promising, but this drug class has not been used at population scale for decades. Rare adverse events may still surface with broader use.
• Pre-diabetes is a legitimate clinical indication that some providers and insurers still treat inconsistently. Document your labs. Know your A1C and fasting glucose numbers.
• Compounded semaglutide is not equivalent to brand-name Wegovy or Ozempic. Formulation, dosing accuracy, and sterility standards differ. This matters for both safety and efficacy expectations.
• Any decision about starting, continuing, or stopping a GLP-1 should involve a licensed provider who knows your full medical history, not a TikTok comment section.